Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25460728 | 1.00 | FFAR4 (0.49) | FFAR4RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL30057753 | 0.83 | MEN1 (0.48) | FFAR4MRGPRX4CYP4F2CYP4A11PPARA | |
| SCHEMBL25170195 | 0.83 | MEN1 (0.48) | FFAR4MRGPRX4CYP4F2CYP4A11PPARA | |
| SCHEMBL3157826 | 0.82 | FFAR4 (0.53) | FFAR4THRATHRBFFAR1 | |
| SCHEMBL15728088 | 0.82 | RXRA (0.51) | FFAR4RXRARXRBRXRGTHRA | |
| SCHEMBL14856202 | 0.79 | PTGS1 (0.51) | FFAR4RXRARXRBRXRGNR3C1 | |
| SCHEMBL16616039 | 0.79 | CYP4F2 (0.54) | FFAR4MRGPRX4CYP4F2CYP4A11PPARA | |
| SCHEMBL8512 | 0.78 | AKR1B1 (0.48) | RXRARXRBRXRGNR3C1THRB | |
| SCHEMBL12886256 | 0.77 | FFAR4 (0.40) | FFAR4MRGPRX4CYP4F2CYP4A11PPARA | |
| SCHEMBL761677 | 0.77 | MAPK14 (0.54) | FFAR4MRGPRX4THRATHRBFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281149-B2 | Modulators of G-protein coupled receptors | CARMOT THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240383960-A1 | Modulators of G-Protein Coupled Receptors | CARMOT THERAPEUTICS INC. (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4337682-A2 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | Carmot Therapeutics Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20230151074-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| CN-115594683-A | Glutaminase GLS1 inhibitor and preparation method and application thereof | 杭州禹胜医药科技有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| WO-2022241287-A2 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383960-A1 | Modulators of G-Protein Coupled Receptors | GIPR, GLP1R, GCGR | FFAR4 135/4885RXRA 462/4885RXRB 382/4885 |
| US-12281149-B2 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | FFAR4 134/4885RXRA 482/4885RXRB 375/4885 |
| US-20230151074-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | FFAR4 134/4885RXRA 482/4885RXRB 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.